Trastuzumab Duocarmazine

Summary

Trastuzumab Duocarmazine (CHEMBL4298178) is a phase-3 clinical-stage antibody drug conjugate (ATC L01FD05); indicated across 10 conditions including neoplasm and breast neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody drug conjugate
• ATC class: L01FD05
• Indications: 10 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298178
Name	Trastuzumab Duocarmazine
Type	Antibody drug conjugate
Max phase	3
ATC	L01FD05

Also known as: SYD-985, SYD985, Trastuzumab duocarmazina, Trastuzumab duocarmazine, TRASTUZUMAB DUOCARMAZINE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
breast neoplasm	3	MONDO:0021100	MONDO:0007254
endometrium neoplasm	2	MONDO:0021251	MONDO:0011962
angiosarcoma	2	MONDO:0016982	EFO:0003968
ovarian carcinoma	1	MONDO:0005140	EFO:0001075
carcinoid tumor	1	MONDO:0005369	EFO:0004243
gastric neoplasm	1	MONDO:0021085	MONDO:0001056

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04205630	PHASE2	COMPLETED	SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
NCT04983238	PHASE1/PHASE2	COMPLETED	Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
NCT04235101	PHASE1	COMPLETED	Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).